Agios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals

MT Newswires Live12-09

Agios Pharmaceuticals (AGIO) said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals.

In the study, mitapivat demonstrated a statistically significant reduction in transfusion burden compared with placebo, the company said.

The company also said the study met all the key secondary endpoints, with mitapivat demonstrating a "statistically significant" reduction in additional measures of transfusion response compared with placebo.

Based on results from two phase 3 studies, the drug developer said it plans to submit regulatory applications for mitapivat to treat transfusion-dependent and non-transfusion-dependent thalassemia patients in the US, EU, Saudi Arabia and the UAE.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490749142?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-09 17:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490749142","market":"sg","top_or_hot":-1,"title":"Agios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals","media":"MT Newswires Live","content":"<html><body><p> Agios Pharmaceuticals (AGIO) said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals.</p><p>In the study, mitapivat demonstrated a statistically significant reduction in transfusion burden compared with placebo, the company said.</p><p>The company also said the study met all the key secondary endpoints, with mitapivat demonstrating a \"statistically significant\" reduction in additional measures of transfusion response compared with placebo.</p><p>Based on results from two phase 3 studies, the drug developer said it plans to submit regulatory applications for mitapivat to treat transfusion-dependent and non-transfusion-dependent thalassemia patients in the US, EU, Saudi Arabia and the UAE.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-09 17:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Agios Pharmaceuticals (AGIO) said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGIO","symbol_name":"Agios Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490749142","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490749142","pubTimestamp":1733737091,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Agios Pharmaceuticals  said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals.In the study, mitapivat demonstrated a statistically significant reduction in transfusion burden compared with placebo, the company said.The company also said the study met all the key secondary endpoints, with mitapivat demonstrating a \"statistically significant\" reduction in additional measures of transfusion response compared with placebo.Based on results from two phase 3 studies, the drug developer said it plans to submit regulatory applications for mitapivat to treat transfusion-dependent and non-transfusion-dependent thalassemia patients in the US, EU, Saudi Arabia and the UAE.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGIO":"Agios Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Agios Pharmaceuticals实现第3阶段主要和次要目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIO":1},"content_text":"Agios Pharmaceuticals (AGIO) said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals.In the study, mitapivat demonstrated a statistically significant reduction in transfusion burden compared with placebo, the company said.The company also said the study met all the key secondary endpoints, with mitapivat demonstrating a \"statistically significant\" reduction in additional measures of transfusion response compared with placebo.Based on results from two phase 3 studies, the drug developer said it plans to submit regulatory applications for mitapivat to treat transfusion-dependent and non-transfusion-dependent thalassemia patients in the US, EU, Saudi Arabia and the UAE.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490749142"}